Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07128303 · ClinicalTrials.gov registry record · Phase 1

Study of GS-5319 in Adults With Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 1
Development phase
178
Enrollment target
8
Study locations

NCT07128303 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 178 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 8 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07128303, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 1
Development phase
178 participants
Enrollment target
8
Study locations

Study Summary

The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme helps in normal growth of cells. The primary objectives of the study are to assess the safety and tolerability of GS-5319 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors and to identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and/or the recommended dose for expansion (RDE).

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG GS-5319

Study Locations (8)

Other

  • Asan Medical Center - Seoul
  • Samsung Medical Center - Seoul
  • Vall d'Hebron Institute of Oncology (VHIO) - Barcelona
  • START Madrid - FJD - Hospital Fundación Jiménez Díaz - Phase I Clinical Trials Unit - Madrid
  • START - Centro Oncológico Clara Campal - Madrid

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Texas

  • START San Antonio - San Antonio

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2025-08-28
Est. Completion 2028-05
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07128303

The ClinicalTrials.gov registry entry for NCT07128303 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which GS-5319 is the first listed.

NCT07128303 reports 8 study locations spanning 4 distinct geographic areas - top geographies include Other, Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT07128303 about?

NCT07128303 is a clinical study titled "Study of GS-5319 in Adults With Solid Tumors". The goal of this clinical study is to learn more about the study drug, GS-5319, its dosing, safety and tolerability in adults with solid tumors, where the participants show a specific gene alteration in the tumor. The gene helps produce methylthioadenosine phosphorylase (MTAP) enzyme. MTAP enzyme he...

What is the current status of trial NCT07128303?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2025-08-28. Estimated completion is 2028-05.

What conditions does trial NCT07128303 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT07128303?

The interventions under investigation include: GS-5319 (DRUG).

Who is sponsoring clinical trial NCT07128303?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07128303 being conducted?

This trial has 8 study locations across Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.